Biotech M&A Tumbles to Lowest in a Decade

Biotech companies have lost their allure, with tougher regulation sending dealmaking in a sector long regarded as a hotbed of mergers and acquisitions to the lowest level in more than a decade.

The sector has seen just 116 deals this year, according to pharma data group Evaluate, down 18% from 2020. The total value of deals struck this year hit $81 billion, a third lower than 2020.

Read the full report: Financial Times

Asian Markets Rally As Pharma Chief Backs Vaccines On Omicron

Beijing Biotech Firm Banks on GM Corn in Bid to be China’s Monsanto

Beijing Slams US Sanctions On Chinese Drug-Making Firms

George Russell

George Russell is a freelance writer and editor based in Hong Kong who has lived in Asia since 1996. His work has been published in the Financial Times, The Wall Street Journal, Bloomberg, New York Post, Variety, Forbes and the South China Morning Post.